Daily intake of short-chain fatty acids and its effects on metabolic health
The Impact of 12 Weeks Intervention With Plant-based Oat Drink Rich in Short-chain Fatty Acids on Postprandial Lipidemia in Individuals at Risk for Metabolic Syndrome
This study is testing whether drinking a daily beverage with short-chain fatty acids can help people at risk for metabolic syndrome improve their heart and metabolic health over 12 weeks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | KU Leuven Academic / other |
| Locations | 1 site (Leuven, Vlaams-Brabant) |
| Trial ID | NCT06951386 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of a daily drink enriched with short-chain fatty acids (SCFAs) on cardiometabolic health in individuals at risk for metabolic syndrome over a 12-week period. Participants will be randomly assigned to consume either the SCFA-enriched drink or a control oat drink. Key metabolic parameters such as blood pressure, body weight, waist and hip circumference, body composition, energy expenditure, glucose, insulin, and blood lipids will be measured before and after the intervention. The study aims to determine if daily SCFA intake can improve these health markers.
Who should consider this trial
Good fit: Ideal candidates are adults with central obesity and at least one additional risk factor for metabolic syndrome.
Not a fit: Patients with gastrointestinal disorders or those on specific diets such as weight loss or vegan may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to dietary recommendations that improve cardiometabolic health and reduce the risk of metabolic syndrome.
How similar studies have performed: Other studies have shown promising results with dietary interventions involving short-chain fatty acids, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * male and female participants * central obesity ( BMI ≥ 25 kg/m² or waist circumference ≥ 80 cm for women/ ≥ 94 cm for men) * One additional risk factor for metabolic syndrome: 1. Insulin resistance (HOMA-IR ≥ 1.7 or fasting glucose ≥ 100 mg/dl) 2. Triglyceride concentration ≥ 150 mg/dl 3. HDL-cholesterol \< 40 mg/dl for women/ \< 50 mg/dl for men 4. Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg * knowledge of English Exclusion Criteria: * gastrointestinal disorders such as IBD, IBS, celiac disease, chronic constipation, chronic diarrhoea * history of abdominal surgery, except for appendectomy * Use of antihypertensive, cholesterol lowering, glucose-regulating drugs and corticosteroids * Use of antibiotics 3 months prior to the start or during the study * Use of probiotics and prebiotics 2 weeks prior to the start of the study/ during the study * Being on weight loss, gluten-free, lactose-free or vegan diet * Pregnancy, lactation or wish to become pregnant * Previous or current substance/ alcohol dependence or abuse * Hyper- or hypothyroidism * Allergy or intolerance to oat milk
Where this trial is running
Leuven, Vlaams-Brabant
- KU Leuven/ UZ Leuven — Leuven, Vlaams-Brabant, Belgium (Recruiting)
Study contacts
- Principal investigator: Kristin Verbeke, Prof. — KU Leuven
- Study coordinator: Riet Rosseel, Msc
- Email: riet.rosseel@kuleuven.be
- Phone: +3216373428
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.